LAB Stock Recent News

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market.

The Dow Jones index closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

The Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024 President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m.

Standard BioTools Inc. (NASDAQ:LAB ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants David Holmes - IR Michael Egholm - President and CEO Jeff Black - CFO Conference Call Participants Matt Stanton - Jefferies Dan Brennan - TD Cowen Paul Knight - KeyBanc Operator Good day and welcome to the Standard BioTools Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Standard BioTools (LAB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.14 per share a year ago.

Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that Jeffrey Black, Chief Financial Officer, will resign from the Company, effective August 31, 2024, to accept an opportunity at another public company.

Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024  Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (NASDAQ: LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024.

MEXICO CITY , July 22, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V . (BMV: LABB) ("Genomma Lab" or "the Company"), a leading company in the pharmaceutical and personal care industry in Mexico with a growing international presence, announces that it has secured a long-term credit line, refinanced financial liabilities, and obtained the release of real estate collateral tied to existing loans.

SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market.